Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its tradipitant development program. https://mma.prnewswire.com/media/2090054/VandaLogo_Logo.jpg On September 18, 2024, the U.S. Food and Drug Administration (FDA) declined to approve Vanda’s New Drug Application (NDA) of tradipitant for the treatment of symptoms in gastroparesis, providing Vanda with a Complete Response Letter (CRL). Gastroparesis is a […]

Touchstone Bankshares, Inc. (the “Company”) (OTC Pink: TSBA) announced today that its Board of Directors has declared a pro rata annual cash dividend in anticipation of its previously announced merger (the “Merger”) with First National Corporation (“First National”) (NASDAQ: FXNC). https://mma.prnewswire.com/media/2472015/TSB_Bankshares_Navy_Blue_Horiz_Web__002_Logo.jpg The pro rata annual cash dividend will be $0.16 per share of the Company’s

Rice University and Baylor College of Medicinehave received $2.8 million in funding from the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), for research on reducing inflammation and lung damage in acute respiratory distress syndrome (ARDS) patients. The study, titled “Cell Based Immunomodulation to Suppress Lung Inflammation

Edwards will advance Keeper’s mission to empower organizations with industry-leading privileged access management and robust cybersecurity solutions Keeper Security, a leading provider of zero-trust and zero-knowledge cybersecurity software, is pleased to announce the appointment of James Edwards as Senior Director of Engineering. Edwards joins Keeper Security from Delinea, where he worked as the Director of

AHEAD, a leading provider of enterprise cloud solutions, announced today the appointment of June Yang to its Board of Directors. Yang, a seasoned cloud computing and artificial intelligence expert, will accelerate the company’s growth in hybrid cloud and AI-driven business services. https://mma.prnewswire.com/media/2508836/June_Yang.jpg Yang brings extensive experience in hybrid cloud technology and AI to AHEAD’s leadership

Skyrocket Licensed OpenAI GPT-4o and ElevenLabs’ AI Voice Technology to Create PLAi: Poe the Ai Story Bear And Put the Power of Storytelling in Children’s Hands Skyrocket, a leading toy company known for producing award-winning and innovative tech toys, is excited to introduce PLAi: Poe the Ai Story Bear, the first and only cuddly plush

HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting regulatory sites on proteins referred to as “natural hotspots,” today announced the appointment of Alison O’Neill, M.D., as Chief Medical Officer. https://mma.prnewswire.com/media/1914271/HotSpot_Therapeutics_Logo.jpg “I am thrilled to welcome Alison, an accomplished industry leader, to HotSpot,” said Jonathan Montagu,

Alithya is honored by Microsoft for outstanding sales achievements and innovation Alithya Group inc. (TSX: ALYA) (“Alithya”)has been selected by Microsoft for the Business Applications 2024-2025 Microsoft Inner Circle award, earning a spot for the 19th time. Inner Circle participation is based on sales achievements that rank Alithya in the top echelon of Microsoft’s Business

— Aramchol is the most clinically advanced, first-in-class, Stearoyl-CoA desaturase1 (SCD1) oral inhibitor, demonstrating in Ph2 and Ph3 (open label part) an excellent safety profile with metabolic and anti-fibrotic effects. — Galmed raised an aggregate of $7.5 million in warrant exercises and drawdowns on its recently adopted equity line Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed”

— Overall survival (OS) results from BRACELET-1 corroborate results of previous randomized IND-213 breast cancer study — Together, these two studies support the compelling potential ofpelareorep-based combination therapy to benefit patients with advanced or metastatic HR+/HER2- breast cancer — Oncolytics Biotech is moving forward to secure funding for a registration-enabling study of pelareorep-based therapy in